REBETRON (TM) Combination Therapy

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved June 1998

Specific Treatments:

hepatitis C

General Information

Schering-Plough Corporation announced that the Food and Drug Administration (FDA) has approved the combination use of REBETOL (TM) (ribavirin, USP) Capsules and INTRON A (R) (interferon alfa-2b, recombinant) Injection, to be marketed as REBETRON (TM) combination therapy, for the treatment of chronic hepatitis C in patients with compensated liver disease who have relapsed following alpha interferon therapy. Prior to REBETRON (RM) combination therapy, the only drugs approved in the US for treating hepatitis C had been alpha interferons.